N
N. Andratschke
Researcher at University of Zurich
Publications - 23
Citations - 473
N. Andratschke is an academic researcher from University of Zurich. The author has contributed to research in topics: Positron emission tomography & Radiosurgery. The author has an hindex of 10, co-authored 23 publications receiving 339 citations. Previous affiliations of N. Andratschke include Ludwig Maximilian University of Munich & University of Rostock.
Papers
More filters
Journal ArticleDOI
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
N. Andratschke,H. Alheid,Michael Allgäuer,Gerhild Becker,Oliver Blanck,Judit Boda-Heggemann,Thomas B. Brunner,Marciana-Nona Duma,Sabine Gerum,Matthias Guckenberger,Guido Hildebrandt,Rainer J. Klement,V. Lewitzki,C. Ostheimer,Alexandros Papachristofilou,Cordula Petersen,Thomas Schneider,Robert Semrau,Stefan Wachter,Daniel Habermehl +19 more
TL;DR: After an initial learning curve with regards to total cumulative doses, consistently high biologically effective doses have been employed translating into high local tumor control at 1 and 2 years and overall survival is mainly influenced by histology and metastatic tumor burden.
Journal ArticleDOI
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Solange Peters,Enriqueta Felip,Urania Dafni,Claus Belka,M. Guckenberger,Antonio Irigoyen,E. Nadal,A. Becker,H. Vees,Miklos Pless,Alex Martinez-Marti,Amanda Tufman,Maarten Lambrecht,N. Andratschke,A.-C. Piguet,M. Kassapian,H. Roschitzki-Voser,Manuela Rabaglio-Poretti,Rolf A. Stahel,Johan Vansteenkiste,Dirk De Ruysscher +20 more
TL;DR: The early safety IA provides evidence that the addition of nivolumab to concurrent CRT is safe and tolerable regarding the 6-month rate of pneumonitis grade ≥3 at the one-sided significance level of 5%.
Journal ArticleDOI
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Stephanie Tanadini-Lang,Juliane Rieber,Andrea Riccardo Filippi,Mette Marie Fode,Jan Streblow,Sonja Adebahr,N. Andratschke,N. Andratschke,Oliver Blanck,Judit Boda-Heggemann,Marciana-Nona Duma,M.J. Eble,Iris Ernst,Michael Flentje,Sabine Gerum,Peter Hass,Christoph Henkenberens,Guido Hildebrandt,Detlef Imhoff,H. Kahl,Natalie Désirée Klass,Robert Krempien,Fabian Lohaus,Fabian Lohaus,Cordula Petersen,E. Schrade,Thomas G. Wendt,Andrea Wittig,Morten Høyer,Umberto Ricardi,Florian Sterzing,Florian Sterzing,Matthias Guckenberger +32 more
TL;DR: A nomogram for prediction of overall survival after stereotactic body radiotherapy (SBRT) for pulmonary metastases was developed and externally validated and might be helpful for interdisciplinary discussion and evaluation of local and systemic treatment options in the oligo-metastatic setting.
Journal ArticleDOI
Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases.
Ralph Bundschuh,N. Andratschke,Julia Dinges,M.N. Duma,Sabrina T. Astner,M. Brügel,Sibylle Ziegler,Michael Molls,Markus Schwaiger,Markus Essler +9 more
TL;DR: FDG-PET can distinguish vital tumor tissue and scar tissue, and therefore alters the GTV especially in patients with previous local treatment, and reduces the interobserver variability significantly compared to MRI.
Journal ArticleDOI
Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy
Markus Essler,J. Wantke,B. Mayer,K. Scheidhauer,Ralph Bundschuh,Bernhard Haller,Sabrina T. Astner,Michael Molls,N. Andratschke +8 more
TL;DR: PET/CT performed 1 year after SBRT can reliably identify local recurrence and therefore help to clarify unclear CT findings and may help to stratify lung cancer patients for additional treatment 1 year after S BRT.